GeneTex employs an innovative production platform and enhanced validation strategies to create reliable and inexhaustible recombinant monoclonal antibodies for essential molecular virology applications.
As the world’s population emerges from the life-changing realities of the SARS-CoV-2 pandemic, the biomedical research community reminds us that this will not be the last virus that threatens humankind. Coronaviruses, flaviviruses, influenza viruses, filoviruses, respiratory syncytial virus, noroviruses, and many other viral pathogens continue to cause morbidity and death across the planet. Presently there are at least 220 viruses representing 23 families known to infect humans, with several new viruses being identified each year (1). Importantly, perhaps 70% of human pathogens are zoonotic in origin, and it is likely that new viral threats will arise from birds and mammals (1). Various alphaviruses (e.g., Chikungunya and the equine encephalitis viruses), bunyaviruses (e.g., Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, and hantavirus), and arenaviruses (e.g., Lassa virus) also pose ongoing danger. The development of vaccines and antiviral therapies is utterly dependent on understanding their basic biology through academic research (2).
Antibodies are essential reagents for molecular virology research and diagnostics development, and recombinant antibodies have become the preferred reagents for both basic molecular virology and diagnostics due to their defined sequence, consistent performance, and inexhaustible supply. Increasing the availability and diversity of recombinant antibodies for virologists remains a challenge in the commercial antibody market. GeneTex, an established antibody manufacturer, is committed to supporting molecular virology and other biomedical research by pivoting all of its new production to the creation of recombinant rabbit monoclonal antibodies. The methodology involves multi-parameter FACS-based isolation of antigen-specific IgG+ memory B cells from an immunized rabbit with subsequent antibody heavy and light chain cloning and expression in mammalian cells (3). The generated antibodies are then thoroughly validated for one or more standard applications relevant to molecular virology, including western blot, immunohistochemistry, immunocytochemistry, ELISA, and flow cytometry. This antibody development/validation platform has already been expanded to manufacture recombinant reagents against other highly pathogenic human and animal viruses. New recombinant antibodies to viral proteins of Chikungunya virus, human papillomavirus, Lassa virus, Nipah virus, noroviruses, respiratory syncytial virus, Venezuelan equine encephalitis virus, and Zika virus have already been produced, as has an extensive line of recombinant reagents for various influenza proteins. These products complement already established lines of well-validated, and frequently cited, standard polyclonal and hybridoma-based monoclonal antibody collections for almost all the major flaviviruses, influenza viruses, enteroviruses, and Ebola virus, among many others. The same focus is being directed at antibodies against key proteins of major veterinary viruses, including African swine fever virus, Porcine circovirus type 2, and porcine reproductive and respiratory syndrome virus. An important goal for GeneTex is to transition successful virology antibodies presently in traditional polyclonal and monoclonal formats to fully recombinant status.
GeneTex understands that pathogenic viruses will continue to endanger both humankind and the animals on which humans depend. Supplying the necessary tools for scientists to develop essential vaccines and antivirals through research is how GeneTex can contribute to countering this threat.
| Influenza B virus Hemagglutinin (HA) antibody [HL2208] (GTX638212) |
| Influenza B virus Nucleoprotein antibody [HL1069] (GTX636100) |
| Influenza B virus Neuraminidase (NA) antibody [HL1476] (GTX636950) |
| Chikungunya virus E1 antibody [HL2069] (GTX637973) |
| Chikungunya virus nsP2 antibody [HL1488] (GTX636962) |
Sandwich ELISA
Capture: ASFV p54 antibody [HL1286] (GTX636700)
Detection: HRP-conjugated ASFV p54 antibody [HL1289] (GTX636703)
Lateral Flow Assay
Capture: ASFV p54 antibody [HL1289] (GTX636703)
Detection: ASFV p54 antibody [GT1075] (GTX635691)
| Hepatitis D virus Large delta + Small delta protein antibody [HL1053] (GTX636028) |
| Hepatitis D virus Large delta protein antibody [HL1051] (GTX636026) |
| Zika virus NS2B protein antibody [HL2151] (GTX638129) |
| Zika virus NS4B protein antibody [HL1663] (GTX637261) |
| Zika virus NS5 protein antibody [HL2154] (GTX638132) |
We gladly support you by keeping you updated on our latest products and the developments around our services.
Direct contact technical support
Find products for your research
